Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of linaprazan glurate versus lansoprazole for healing erosive esophagitis due to GERD
2024-518714-31-00Phase 3Completed
- Sponsor
- Cinclus Pharma
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3, randomised, double-blind trial of linaprazan glurate in erosive esophagitis (EE) and gastroesophageal reflux disease (GERD) (3 arms), sponsored by Cinclus Pharma. Primary endpoint: Healing of erosive esophagitis at Week 4 in baseline Los Angeles grade C/D participants. Started Oct 2025; status: completed.
02
Drugs
linaprazan glurate
03
Conditions
erosive esophagitis (EE)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on 2024-518714-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518714-31-00.